Relapse refractory and high risk

In this project we will generate patient-derived xenograft models from individual pediatric relapse and refractory leukemia patients to complement the original patient material for molecular analyses, flow cytometry and drug response profiling (ex vivo and in vivo). This way, the project can add indispensable information to assign the patient to the most appropriate early phase clinical trial.